Close Menu

Huntington's disease

NPR reports on a clinical trial examining an antisense oligonucleotide drug for Huntington's disease.

The test will run on Oxford Nanopore's MinIon and will be used as a reflex test when the standard PCR test does not give a clear answer.

The researchers studied edits generated by more than 40,000 gRNAs and gathered data for more than 109 mutational outcomes to create the software.

Duty to Tell?

A UK woman sues a hospital for not telling her of her father's genetic testing results, the Guardian reports.

This Week in Science

In Science this week: molecular drivers of small cell neuroendocrine carcinomas, and more.

This Week in PLOS

In PLOS this week: Huntington's disease modifiers, possible new Chikungunya virus subgroup, and more.

Six microRNAs appeared to be present at enhanced levels in cerebrospinal fluid from symptom-free individuals with characteristic Huntington disease gene expansions.

Just Don't Tell Me

According to Slate, some people prefer not to know their genetic risk of certain diseases.

This Week in Cell

In Cell this week: regulatory changes in pancreatic cancer, metabolic shifts in Alzheimer's disease, and more.

The researchers observed that eliminating these microsatellite repeat expansion RNAs in patient cells reversed some hallmark features of the diseases.

Pages

The Hill reports President Donald Trump issued an executive directing federal agencies to cut the number of board and advisory committees they have.

The New York Times reports that researchers are combining tools to more quickly develop crops to feed a growing population and cope with shifting climates.

Scientists in Canada are looking to the UK's plan to sequence children with rare conditions for inspiration, the National Post reports.

In PNAS this week: copy number changes arose during polar bear evolution, genomic and transcriptomic analysis of the Siberian hamster, and more.